Please login to the form below

Not currently logged in
Email:
Password:

Acumen appoints new strategy director

Thomas Bols will focus on reinforcing Acumen’s healthcare practice

Thomas BolsIndependent consultancy Acumen Public Affairs has named Thomas Bols as its new strategy director, a role that will see him focus on reinforcing Acumen’s healthcare practice.

Bols has expertise in assisting healthcare companies with strategic communications and public affairs projects and his career history has seen him in variety of consulting and corporate positions including Amgen, Merck and Biogen.

Commenting on his appointment, Bols said: “I’m really motivated about taking my career and Acumen’s business forward - I think there is a real opportunity to bring my experience to healthcare clients in Brussels as well as in capitals, and of course at a global level.”

Bols has also worked in the areas of market access, government affairs, public affairs, health policy and corporate communications to name a few and he has also advised companies engaging with policy makers, patient representatives, media, regulators and payers.

Elaine Cruikshanks, founding partner of Acumen, said: “We are really excited about the prospect of Thomas working with us and proud that we have been able to attract a professional with such a wealth of in-house and consultancy healthcare experience to offer clients.”

8th March 2018

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...